Insurance Status Mediates Racial, Ethnic Inequities in Cervical Cancer
A larger proportion of patients with private or Medicare insurance received a diagnosis of early-stage cervical cancer.
A larger proportion of patients with private or Medicare insurance received a diagnosis of early-stage cervical cancer.
Quality metrics for cancer screening tests vary across cancer types, but most metrics are not supported by evidence, a study suggests.
Patients age 65 and older are more likely to be diagnosed with late-stage cervical cancer and have a lower rate of late-stage survival at 5 years.
Compared with the general population, survivors of gynecologic cancers have a higher risk of sexual dysfunction 1 to 5 years after cancer diagnosis.
A report from the American Cancer Society reveals trends in cancer incidence and mortality over time and includes projections for 2023.
Countries with lower a Human Development Index had a higher incidence of cervical cancer.
The percentage of women who received at least 1 cytology or HPV test decreased from 18.9% (2.9 million) in 1999 to 8.5% (1.3 million) in 2019.
New data show that, in the last 2 decades, the incidence of cervical cancer in the United States has declined or remained stable for most age groups.
Screening for breast, cervical, and colorectal cancer decreased from prepandemic levels in early 2020, rebounded in late 2020, and decreased again in 2021.
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.